---
title: "Kewaunee Scientific Corp FY 2026: Revenue $282M, EPS $3.22— 10-K Summary"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/291010239.md"
description: "Kewaunee Scientific Corp reported FY2026 revenue of $282M, up 17.3% YoY, driven by the Nu Aire acquisition. However, net income fell 9.7% to $10.47M and diluted EPS dropped 15.9% to $3.22 due to profitability pressures. The acquisition expanded product offerings and global reach in life sciences. Management completed integration while maintaining gross margins. Order backlog declined to $165.9M, though international segments showed improvement."
datetime: "2026-06-26T21:15:02.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/291010239.md)
  - [en](https://longbridge.com/en/news/291010239.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/291010239.md)
generator: "portal-rs"
---

# Kewaunee Scientific Corp FY 2026: Revenue $282M, EPS $3.22— 10-K Summary

Kewaunee Scientific Corp reported fiscal 2026 results with revenue of $282M, downbeat net income of $10.47M and diluted EPS of $3.22, reflecting growth from acquisitions but pressure on profitability versus the prior year.

**Financial Highlights**

Metric

Current year

Prior year

YoY change

Revenue¹

$282M

$240.47M

17.3%

Net income²

$10.47M

$11.58M

(9.7%)

Diluted EPS³

$3.22

$3.83

(15.9%)

*¹ Reported as “Net sales”. ² Reported as “Net earnings”. ³ Reported as “Diluted earnings per share attributable to Kewaunee Scientific Corporation stockholders”.*

**Business Highlights**

-   Revenue growth was driven largely by the November 2024 acquisition of Nu Aire, which broadened Kewaunee’s product portfolio and distribution.
-   Acquisition expanded channels and geographic reach, strengthening presence in life sciences, healthcare and in markets including India, Asia and Africa.
-   Nu Aire added products such as biosafety cabinets, incubators and ultralow freezers, enhancing lab solutions and brand momentum.
-   Management completed integration efforts and invested in corporate scaling while maintaining consistent gross margins amid higher sales.
-   Order backlog declined to $165.9M; international backlog improved with India project deliveries, but overall timing of project execution remains variable.

Original SEC Filing: KEWAUNEE SCIENTIFIC CORP /DE/ \[ KEQU \] - 10-K - Jun. 26, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [KEQU.US](https://longbridge.com/en/quote/KEQU.US.md)

## Related News & Research

- [Kewaunee Scientific Posts Record $282M Revenue, Maps Fiscal 2027 Growth Investments](https://longbridge.com/en/news/297409499.md)
- [Kewaunee Scientific holds annual shareholder meeting](https://longbridge.com/en/news/297181638.md)
- [EXL announces Departure of Vivek Jetley, President and Head of Insurance, Healthcare and Life Sciences | EXLS Stock News](https://longbridge.com/en/news/297794111.md)
- [KEQU: FY2026 revenue and EBITDA surged, driven by platform integration and global expansion](https://longbridge.com/en/news/297077774.md)
- [Kewaunee Scientific posts presentation for 2026 annual shareholder meeting](https://longbridge.com/en/news/297074649.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**